Correlation between the in vitro ATP-based chemosensitivity assay and HER2/neu expression in women with breast cancer

Journal of International Medical Research

Volumn 35, Issue 6, 2007, Pages 753-761

  Woo, S U ^a   Bae, Jeoug Won ^a   Kim, H G ^a   Choi, S H ^b   Kang, D H ^b   Lee, J B ^a   Koo, B W ^a  

^a Korea University College of Medicine   (South Korea)

^b Isu Abxis Co Ltd   (South Korea)

Author keywords

5 Flourouracil; Anticancer Agents; Breast cancer; Chemosensitivity; Doxorubicin; HER2 neu; Hormone receptor; Methotrexate; Vinorelbine

Indexed keywords

DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GEMCITABINE; METHOTREXATE; NAVELBINE; PACLITAXEL;

ADENOSINE TRIPHOSPHATE BASED CHEMOTHERAPY RESPONSE ASSAY; ADULT; AGED; ANALYTIC METHOD; BREAST CANCER; CANCER CELL CULTURE; CANCER PATIENT; CELL DEATH; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; METASTASIS POTENTIAL; PROTEIN EXPRESSION; RECURRENT CANCER; REVIEW;

EID: 36949033840     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000703500603     Document Type: Review

References (24)

1. Sargent J, Elgie: A, Taylor CG, et al: The identification of drug resistance in ovarian cancer and breast cancer: application of the MTT assay. Contrib Gynecol Obstet 1994; 19: 64-75.
2. Wilson JK, Sargent JM, Elgie AW, et al: - feasibility study of the MTT assay for chemosensitivity testing in ovarian malignancy. Br J Cancer 1990; 62: 189-194.
3. Fossati R, Confalonieri C, Torri V, et al: Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998; 16: 3439-3460.
4. Sjostrom J, Blomqvist C, Mouridsen H, et al: Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999; 35: 1194-1201.
5. Orr JW Jr, Orr P, Kern DH: Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance. Cancer J Sci Am 1999; 5: 174-178.
6. Allred DC, Clark GM, Tandon AK, et al: HER2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992; 10: 599-605.
7. Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992; 10: 1049 -1056.
8. Weisenthal LM, Kern DH: Prediction of drug resistance in cancer chemotherapy: the Kern and DiSC assays. Oncology (Williston Park) 1991; 5: 93-103; discussion 4, 11-14, 17-18.
9. Cortazar P, Johnson BE: Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J Clin Oncol 1999; 17: 1625-1631.
10. Kang SM, Park MS, Chang J, et al: A feasibility study of adenosine triphosphate-based chemotherapy response assay (ATP-CRA) as a chemosensitivity test for lung cancer. Cancer Treat Res 2005; 37: 223-227.
11. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990; 8: 1483-1496.
12. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 930-942.
13. Olivotto IA, Bajdik CD, Plenderleith IH, et al: Adjuvant systemic therapy and survival after breast cancer. N Engl J Med 1994; 330: 805-810.
14. Cree IA, Kurbacher CM: Individualizing chemotherapy for solid tumors - is there any alternative? Anticancer Drugs 1997; 8: 541-548.
15. Maehara Y, Anal H, Tamada R, et al: The ATP assay is more sensitive than the succinate dehydrogenase inhibition test for predicting cell viability. Eur J Cancer Clin Oncol 1987; 23: 273-276.
16. O'Meara AT, Sevin BU: Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer. Gynecol Oncol 2001; 83: 334-342.
17. Ng TY, Ngan HY, Cheng DK, et al: Clinical applicability of the ATP cell viability assay as a predictor of chemoresponse in platinum-resistant epithelial ovarian cancer using nonsurgical tumor cell samples. Gynecol Oncol 2000; 76: 405-408.
18. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/ neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
19. Slamon DJ, Clark GM, Wong SG, et an: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science 1987; 235: 177-182.
20. Pritchard KI, Shepherd LE, O'Malley FP, et al: HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006; 354: 2103-2111.
21. Jacquemier J, Penault-Llorca F, Viens P, et al: Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression. Anticancer Res 1994; 14: 2773-2778.
22. Rozan S, Vincent-Salomon A, Zafrani B, et al: No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 1998; 79: 27-33.
23. Guarneri V, Broglio K, Kau SW, et al: Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24: 1037-1044.
24. Takamura Y, Kobayashi H, Taguchi T, et al: Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers. Int J Cancer 2002; 98: 450-455.